DexCom, Inc. (NASDAQ:DXCM) EVP Jereme M. Sylvain Sells 2,090 Shares

DexCom, Inc. (NASDAQ:DXCM) EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

DexCom Stock Down 0.9 %

NASDAQ DXCM opened at $86.83 on Friday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a market cap of $33.92 billion, a PE ratio of 51.99, a PEG ratio of 2.22 and a beta of 1.12. The firm has a 50-day simple moving average of $80.77 and a 200 day simple moving average of $76.21.

Institutional Trading of DexCom

Institutional investors have recently modified their holdings of the company. Versant Capital Management Inc acquired a new position in shares of DexCom in the fourth quarter valued at $25,000. Riverview Trust Co raised its stake in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. Heck Capital Advisors LLC bought a new position in shares of DexCom during the 4th quarter worth about $38,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of DexCom during the 3rd quarter valued at about $57,000. Finally, Covestor Ltd increased its stake in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on DXCM shares. JPMorgan Chase & Co. increased their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Royal Bank of Canada cut their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Oppenheimer lowered their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, Sanford C. Bernstein boosted their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.29.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.